HB 625 shifts responsibility for collecting fees from research facilities to the Maryland Department of Agriculture, replacing the current system under the Department of Health. It requires facilities submitting USDA Form 7023 (for animal testing) to pay annual contributions based on animal count: $5,000 for ≤100 animals, $10,000 for 101-500, $55,000 for 501-5,000, and $75,000 for over 5,000. Funds collected will support the Human-Relevant Research Fund established under Maryland’s Economic Development Article. The bill repeals existing health code provisions and creates new agriculture code sections for this fee structure, effective October 2026.
HB 1367 establishes a Commission on Re-Imagining Health Care in Maryland to study and recommend changes for a new statewide healthcare system. The commission, composed of 20 appointed members including state officials, healthcare providers, insurers, county representatives, and community members, will examine how healthcare is delivered in other regions and address issues like provider shortages, cost balancing, and system integration. It will specifically study how to create a patient-centered system covering all health needs, eliminate access barriers, and ensure financial sustainability for all Maryland residents. The commission’s final recommendations, due by 2028, would guide potential future policy changes but do not enact any immediate healthcare reforms.
HB 1376 requires Maryland's Medicaid (Maryland Medical Assistance Program) and Children's Health Program to provide a review within 3 business days for transfer requests to special pediatric hospitals when requested by the hospital or referring provider. It mandates retrospective reviews if a transfer is denied as "not medically necessary," with providers reimbursed for "administrative days" (days a patient remains without transfer) during the review process. The bill directly affects special pediatric hospitals - facilities serving children under 22 or those 2+ years old with co-occurring physical/behavioral health conditions - and their referring providers. Key provisions include eliminating prior authorization requirements for transfers while establishing strict timelines and reimbursement for administrative delays during appeals. This bill updates existing Medicaid and insurance rules to streamline transfers to specialized pediatric care facilities.
SB 772 requires the Maryland Department of Health to create and maintain a public database of employment training and job placement programs. The database will help residents find opportunities that can lead to eligibility for Medicaid (Maryland Medical Assistance Program) and SNAP (Supplemental Nutrition Assistance Program), including program details, application steps, and direct contact options. The Department must update the database every 30 days and assist individuals in enrolling in listed programs. Other state agencies, including the Department of Labor and Department of Human Services, must recommend programs for inclusion. This bill directly affects Maryland residents seeking to improve employment prospects while maintaining access to critical health and nutrition benefits.
HB 1016 invalidates noncompete and conflict-of-interest clauses in employment contracts for certain employees if their employer relocates the majority of its employees or principal business location outside Maryland. It directly affects low-wage workers (earning ≤150% of state minimum wage), healthcare workers providing direct patient care (earning ≤$350,000 annually), and veterinary professionals. For high-earning healthcare workers ($350,000+), the bill allows limited 1-year noncompete restrictions within 10 miles of their prior workplace. The law takes effect October 1, 2026, and applies only to contracts signed after that date.
HB 1012 authorizes counties and municipalities in Maryland to establish local suicide fatality review teams, which directly affect local governments and public health agencies. These teams must include representatives from health departments, law enforcement, schools, hospitals, and mental health professionals to review suicide cases and identify systemic factors. The bill requires teams to coordinate with the state suicide review committee and mandates confidentiality for case discussions, exempting meetings about individual cases from public disclosure laws and protecting sensitive information. It also prohibits public disclosure of identifying details about deceased individuals or those affected by suicide, ensuring privacy while allowing teams to develop prevention recommendations.
HB 772 establishes a workgroup within Maryland's Health Care Commission to develop fairer reimbursement methods for certified community behavioral health clinics and outpatient mental health centers. The workgroup will study current costs, staffing models, and federal requirements to create transparent, cost-based payment systems, comparing approaches used in other states. It must submit an interim report by December 2026 and a final report by October 2027 with specific recommendations, implementation options, and fiscal estimates. The bill does not require immediate rate changes or new funding, but rather sets a process for future policy decisions based on the workgroup's findings.
HB 1533 (the Crown and Care Act) bans 12 specific harmful ingredients - including certain phthalates, formaldehyde, mercury, and PFAS chemicals - from cosmetic products sold in Maryland. It directly affects cosmetic manufacturers, retailers, and salons by prohibiting the sale or distribution of products containing these ingredients, with limited exceptions for unavoidable trace amounts from manufacturing processes. The bill authorizes the Maryland Department of Health to investigate complaints, inspect businesses, and enforce penalties, while allowing consumers harmed by violations to seek civil damages and attorney fees. This law aims to protect public health by reducing exposure to chemicals linked to health risks like skin irritation and potential long-term harm.
SB 656 bans 12 specific harmful chemicals in cosmetics sold in Maryland, including formaldehyde, mercury, and certain PFAS chemicals. It creates civil liability for manufacturers or sellers who violate this ban, allowing consumers to sue for damages. The Maryland Department of Health gains authority to investigate complaints, inspect businesses, and collect product samples. The law exempts trace amounts of banned ingredients that occur unavoidably during manufacturing. The bill takes effect July 1, 2026.
HB 1135 allows pharmacists in Maryland to order certain vaccinations for patients aged 3 and older without needing to administer the vaccine themselves. Pharmacists must complete 20+ hours of approved training covering vaccine safety, injection techniques, and emergency response, hold current CPR certification, and report all vaccinations to the ImmuNet program. The bill specifically covers influenza, COVID-19, and emergency-use vaccines, and requires pharmacists to refer minors to pediatric care when ordering vaccines. This expands pharmacists' role in vaccine access while maintaining safety protocols and reporting requirements.
